EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Kaempferol inhibits hepatitis B virus replication via ERK/FOXO1 pathway-mediated suppression of the viral core promoter

Wanyu Deng, Zhen Luo, Haifei Yu, Fu Chen, Jiefeng Ding, Chun Dai, Xiaoyong Zhang, Bo Qin, Jie Dou, Min Guo

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2026.1780484 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Wanyu Deng und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Science, Shangrao Normal University, Shangrao, China. Hauptthemen laut MEDLINE: Hepatitis B virus, Virus Replication, Forkhead Box Protein O1, Kaempferols. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chronic hepatitis B virus (HBV) infection continues to pose a significant global health burden, and current therapies rarely target the viral covalently closed circular DNA reservoir. Kaempferol (KP), a major flavonoid found in various herbs and plants, exhibits diverse bioactivities, but its potential anti-HBV activity remains unclear. This study aims to investigate the anti-HBV potential of KP and to elucidate its underlying mechanisms.

Methods

The HBV-infected Huh7D hNTCP cell, viral stable transfection cell HepG2.2.15, as well as a hydrodynamic injection-based chronic HBV infection mouse model, were established to evaluate the antiviral effects of KP. The levels of HBV RNAs, DNA and proteins were detected using ELISA, western blot, qPCR, immunofluorescence and immunohistochemistry. To investigate the mechanisms, viral promoter activities were assessed via dual-luciferase reporter assays, and relevant transcription factors were validated through qPCR and western blot analysis.

Results

KP dose- and time-dependently reduced the levels of viral antigens, RNA, and DNA in vitro , and also significantly lowered viral markers and attenuated HBV-induced hepatic pro-inflammatory cytokines expression in vivo . Furthermore, KP acted in combination with the nucleoside analog entecavir to suppress HBV replication. Mechanistically, KP strongly inhibited the transcriptional activity of the HBV core promoter (Cp), and enhanced the phosphorylation of both extracellular signal-regulated kinase (ERK) and its downstream target forkhead box protein O1 (FOXO1). Importantly, the ERK-specific inhibitor U0126 completely abolished the antiviral effects of KP, confirming that its antiviral activity depended on the ERK/FOXO1 pathway.

Discussion

Collectively, our results indicate that KP activates ERK-dependent FOXO1 phosphorylation, leading to transcriptional repression of the HBV Cp and thereby suppression of viral replication. These findings identify KP as a potential candidate for developing novel therapeutics against chronic HBV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusVirus ReplicationForkhead Box Protein O1KaempferolsPromoter Regions, GeneticAntiviral AgentsMAP Kinase Signaling SystemAnimalsHumansMiceHepatitis B, ChronicDisease Models, AnimalHep G2 CellsExtracellular Signal-Regulated MAP Kinases

Stichwörter der Autor:innen

ERKFOXO1core promoterhepatitis B viruskaempferolphosphorylation

Substanzen

Forkhead Box Protein O1KaempferolskaempferolAntiviral AgentsFOXO1 protein, humanExtracellular Signal-Regulated MAP Kinases

Autor:innen und Institutionen

  • College of Life Science, Shangrao Normal University, Shangrao, China.
  • Department of Tibetan Medicine, University of Tibetan Medicine, Lhasa, China.
  • State Key Laboratory of Natural Medicines, School of Life Science & Technology, China Pharmaceutical University, Nanjing, China.
  • Shaoxing Women and Children's Hospital, Shaoxing, China.
  • Department of General Surgery, Yangzhong People's Hospital Affiliated to Medical College of Yangzhou University, Yangzhong, China.
  • Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Zitieren

APA

Deng, W., Luo, Z., Yu, H., Chen, F., Ding, J., Dai, C., Zhang, X., Qin, B., Dou, J., & Guo, M. (2026). Kaempferol inhibits hepatitis B virus replication via ERK/FOXO1 pathway-mediated suppression of the viral core promoter. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1780484

Vancouver

Deng W, Luo Z, Yu H, Chen F, Ding J, Dai C, et al. Kaempferol inhibits hepatitis B virus replication via ERK/FOXO1 pathway-mediated suppression of the viral core promoter. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1780484

BibTeX
@article{Deng2026,
  author = {Deng, Wanyu and Luo, Zhen and Yu, Haifei and Chen, Fu and Ding, Jiefeng and Dai, Chun and Zhang, Xiaoyong and Qin, Bo and Dou, Jie and Guo, Min},
  title = {Kaempferol inhibits hepatitis B virus replication via ERK/FOXO1 pathway-mediated suppression of the viral core promoter},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2026.1780484}
}
Kostenlos starten →